Scienmag
MAY 17, 2022
These small, circular DNA molecules are used by scientists to introduce new genes into a target organism. Well known for their applications in the production of therapeutic proteins like insulin, plasmids are broadly used in the large-scale production of many bioproducts. Plasmids have extensive use in basic and applied biology.
Pharmaceutical Technology
FEBRUARY 16, 2023
These primarily include oxidative stress caused by the accumulation of reactive oxygen species, telomere shortening, and deoxyribonucleic acid (DNA)/histone methylation patterns. Telomeres are the buffer regions of DNA that cap the ends of chromosomes and prevent chromosomal attrition during DNA replication.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MARCH 28, 2023
Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). The gene-editing technology allows for precise, directed changes to genomic DNA. The system comprises the Cas9 enzyme and a guide RNA.
Pharmaceutical Technology
MAY 15, 2023
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.
FDA Law Blog
JANUARY 5, 2023
One example is the Warning Letter FDA sent to Medtronic in late 2021 concerning a vulnerability in insulin infusion pumps. This was a topic at the December Food and Drug Law Institute conference on Current Developments in Digital Health Technology and Regulation. More updates will follow here as trends develop in 2023.
Roots Analysis
JANUARY 14, 2024
With the increased interest and gradual shift of investment from small molecule drugs to biologics and the establishment of several biologics manufacturing companies / biologics CMOs, more than 250 biologic therapies and vaccines have been developed, globally.
The Pharma Data
DECEMBER 28, 2020
Amphastar’s newly approved synthetic peptide product was determined by the FDA to be bioequivalent and therapeutically equivalent to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar, which has a recombinant DNA (rDNA)-origin. billion, three biosimilar products in development targeting products with a market size of approximately $13.0
Expert insights. Personalized for you.
90 
Let's personalize your content